Anorexia, a deadly psychiatric condition, has seen a rise in hospitalizations among young women in Australia. As researchers explore psilocybin, the magic mushroom compound, for its potential in treating anorexia, new challenges and controversies emerge.
The Promise and the Puzzle of Psilocybin
Psilocybin, with its unique effects on behavior and inflammation, has shown promise in early clinical trials for anorexia nervosa. However, the mechanics behind its effectiveness remain shrouded in mystery. Only about 40% of participants experience symptom reduction, leaving scientists with more questions than answers.
The Scientific Challenge: Unraveling Anorexia's Complexity
Anorexia nervosa carries one of the highest mortality rates among psychiatric disorders. Beyond the physical toll, individuals with anorexia face social challenges, including smaller social circles and impaired emotional empathy. These social deficits share neurobiological roots with depression, anxiety, and OCD, involving serotonin dysfunction and elevated proinflammatory cytokines.
Psychedelics, acting through serotonin receptors, offer a glimmer of hope with their anti-inflammatory properties. Could they be the key to addressing multiple symptoms simultaneously?
Female-Focused Methodology: Uncovering Gender Differences
Dr. Claire Foldi and her team at Monash University employed a female-focused methodology, using the activity-based anorexia (ABA) model in mice. This model combines limited food access with voluntary running wheel access, resulting in starvation-induced hyperactivity, severe weight loss, and elevated anxiety.
Eight-week-old female mice were divided into four groups: ABA, food restriction alone, running wheel access with unlimited food, and standard single housing. Psilocybin was administered at 1.5 mg/kg after mice reached 75-85% of their baseline body weight. Social preference and novelty tests followed, with blood samples collected to measure interleukin-6 levels.
Unexpected Social Patterns: A Twist in the Tale
Contrary to expectations, ABA mice did not exhibit social deficits but showed heightened novelty-seeking behavior, consistently preferring unfamiliar mice. Exercising mice also preferred novel partners, but this preference emerged primarily during the choice phase. Food-restricted mice displayed no such effects.
Psilocybin reduced novelty-seeking in control mice, balancing their time spent with familiar and novel partners. In food-restricted mice, body weight correlated with attention to a novel object over a mouse, indicating increased food-seeking motivation.
Inflammation and Context: Unraveling the Link
Baseline interleukin-6 levels were similar across groups, but psilocybin significantly elevated interleukin-6 in exercising mice, correlating with a greater preference for social novelty. The researchers suggest that prior food restriction disrupted the link between psilocybin, inflammation, and sociability in exercising mice.
Exercise, as a rewarding activity activating dopamine pathways, may create a unique metabolic and immune context, influencing psilocybin's effects.
Implications and Future Directions: Personalized Approaches
Dr. Foldi emphasizes the complexity of translating psychedelics into eating disorder treatment. The study's findings highlight the importance of considering patients' metabolic states, exercise histories, and illness durations, as these factors may influence treatment outcomes. Exercise status and inflammatory profiles could serve as biomarkers for response.
This research advances our understanding of psychedelic science, demonstrating how metabolic state shapes behavioral and immune responses to psilocybin. By focusing on female subjects and systematically comparing experimental conditions, the study provides a framework for personalized approaches in treating eating disorders.
